---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-060850"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:16:13.624894+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics reports Q2 net loss $6.7M; PDUFA date Aug 29 for ONS-5010

## Summary
- Net loss $6.7M ($0.03/sh) vs $19.7M ($0.09) in prior-year Q2.
- Cash $43.7M as of March 31, 2023; expects to fund ops through potential approval in Q3/Q4 2023.
- PDUFA goal date Aug 29, 2023 for ONS-5010 (bevacizumab) for wet AMD.
- Pre-launch commercial activities ongoing; partnership with AmerisourceBergen for distribution.
- MAA for ONS-5010 under EU review; CHMP decision expected early 2024.

## SEC filing metadata
- accession: 0001104659-23-060850
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465923060850/0001104659-23-060850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465923060850/tm2315802d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-060850
- JSON: https://secwatch.observer/filing/0001104659-23-060850.json
- Plain text: https://secwatch.observer/filing/0001104659-23-060850.txt

## Key facts
- Earnings Releases
  Outlook Therapeutics, Inc. reported financial results for second fiscal quarter ended March 31, 2023.
  - Period: second fiscal quarter ended March 31, 2023
  - Result: reported results
  source text: On May 15, 2023, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its second fiscal quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465923060850/0001104659-23-060850-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.